Daiichi Sankyo Co Ltd 4568.T:
TEMPUS ANNOUNCES STRATEGIC COLLABORATION WITH DAIICHI SANKYO TO ADVANCE AI-DRIVEN BIOMARKER DISCOVERY AND CLINICAL DIFFERENTIATION ACROSS AN ADC CLINICAL PROGRAM
TEMPUS AI : DAIICHI SANKYO WILL LEVERAGE TEMPUS' PROPRIETARY FOUNDATION MODELS AND AI EXPERTISE, INCLUDING PRISM2 MULTIMODAL FOUNDATION MODEL